BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 1332634)

  • 1. Cardiovascular risk factors during estrogen-norethindrone and cholecalciferol treatment.
    Myrup B; Jensen GF; McNair P
    Arch Intern Med; 1992 Nov; 152(11):2265-8. PubMed ID: 1332634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve Thai women.
    Jirapinyo M; Theppisai U; Manonai J; Suchartwatnachai C; Jorgensen LN
    Acta Obstet Gynecol Scand; 2003 Sep; 82(9):857-66. PubMed ID: 12911449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
    Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
    Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipids and antioxidative effects of estradiol and sequential norethisterone acetate treatment in a 3-month randomized controlled trial.
    Falkeborn M; Lithell H; Persson I; Vessby B; Naessén T
    Climacteric; 2002 Sep; 5(3):240-8. PubMed ID: 12419082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study.
    Nickelsen T; Creatsas G; Rechberger T; Depypere H; Erenus M; Quail D; Arndt T; Bonnar J;
    Climacteric; 2001 Dec; 4(4):320-31. PubMed ID: 11770189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study.
    Chang TC; Lien YR; Chen M; Cheng SP; Chen RJ; Chow SN
    Acta Obstet Gynecol Scand; 2004 Jul; 83(7):661-6. PubMed ID: 15225192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of continuous combined conjugated estrogen/medroxyprogesterone acetate and 17beta-estadiol/norethisterone acetate on lipids and lipoproteins.
    Odmark IS; Bäckström T; Haeger M; Jonsson B; Bixo M
    Maturitas; 2004 Jun; 48(2):137-46. PubMed ID: 15172088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined hormone replacement therapy with oestradiol and norethisterone acetate: effects in hyperlipidaemia.
    Tonstad S
    Br J Obstet Gynaecol; 1996 May; 103 Suppl 13():45-8. PubMed ID: 8624342
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects on serum lipid and leptin levels of three different doses of norethisterone continuously combined with a fixed dose of 17beta-estradiol for nasal administration in postmenopausal women: a controlled, double-blind study.
    Castelo-Branco C; Palacios S; Vázquez F; Villero J; Ferrer J; Ascaso C; Balasch J
    Fertil Steril; 2007 Aug; 88(2):383-9. PubMed ID: 17561009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipids and clotting factors during low dose transdermal estradiol/norethisterone use.
    Brynhildsen J; Hammar M
    Maturitas; 2005 Apr; 50(4):344-52. PubMed ID: 15780536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of oral continuous 17beta-estradiol plus norethisterone acetate replacement therapy on abdominal subcutaneous fat, serum leptin levels and body composition.
    Yüksel H; Odabaşi AR; Demircan S; Karul A; Kozaci LD; Köseoğlu K; Kizilkaya K; Başak O
    Gynecol Endocrinol; 2006 Jul; 22(7):381-7. PubMed ID: 16864148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of raloxifene and continuous combined hormone therapy on haemostasis variables: a multicenter, randomized, double-blind study.
    Sgarabotto M; Baldini M; Dei Cas A; Manotti C; Luciana Barilli A; Rinaldi M; Benassi L; Bacchi Modena A
    Thromb Res; 2007; 119(1):85-91. PubMed ID: 16499954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy.
    Kim CJ; Min YK; Ryu WS; Kwak JW; Ryoo UH
    Arch Intern Med; 1996 Aug 12-26; 156(15):1693-700. PubMed ID: 8694668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy.
    Ylikorkala O; Lim P; Caubel P
    Clin Ther; 2000 May; 22(5):622-36. PubMed ID: 10868559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of postmenopausal hormone replacement therapy on body fat composition.
    Yüksel H; Odabasi AR; Demircan S; Köseoğlu K; Kizilkaya K; Onur E
    Gynecol Endocrinol; 2007 Feb; 23(2):99-104. PubMed ID: 17454160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of oral and transdermal hormone replacement therapies on serum lipid and lipoprotein concentrations.
    Whitcroft SI; Crook D; Marsh MS; Ellerington MC; Whitehead MI; Stevenson JC
    Obstet Gynecol; 1994 Aug; 84(2):222-6. PubMed ID: 8041534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
    Greenwald MW; Gluck OS; Lang E; Rakov V
    Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone therapy in women in the menopause transition. Randomised, double-blind, placebo-controlled trial of effects on body weight, blood pressure, lipoprotein levels, antithrombin III activity, and the endometrium.
    Khoo SK; Coglan MJ; Wright GR; DeVoss KN; Battistutta D
    Med J Aust; 1998 Mar; 168(5):216-20. PubMed ID: 9539899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of tamoxifen and estrogen replacement therapy on lipid metabolism and some other cardiovascular risk factors. A prospective study in hysterectomised women].
    Imperato F; Marziani R; Perniola G; Ebano V; Fruscella M; Mossa B
    Minerva Ginecol; 2003 Feb; 55(1):87-93. PubMed ID: 12598849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.